Allogeneic hematopoietic stem-cell engraftment and graft failure

Pediatric Transplantation

Volumn 3, Issue SUPPL. 1, 1999, Pages 35-40

  Woolfrey, Ann ^a,b   Anasetti, Claudio ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

Graft failure; Hematopoietic cell transplantation; Marrow transplantation

Indexed keywords

HLA ANTIGEN;

ALLOGENIC BONE MARROW TRANSPLANTATION; CONFERENCE PAPER; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; RISK FACTOR;

CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT REJECTION; GRAFT VS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; PROGNOSIS; RISK ASSESSMENT; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032749553     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00068.x     Document Type: Conference Paper

References (39)

1. ANASETTI C, AMOS D, BEATTY PG, et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989: 320: 197-204.
2. ASH RC, HOROWITZ MM, GALE RP, et al. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant 1991: 7: 443-452.
3. SANTAMARIA P, REINSMOEN NL, LINDSTROM AL, et al. Frequent HLA class I and DP sequence mismatches in serologically (HLA-A, HLA-B, HLA-DR) and molecularly (HLA-DRB1, HLA-DQA1, HLA-DQB1) HLA-identical unrelated bone marrow transplant pairs. Blood 1994: 83: 280-287.
4. PETERSDORF EW, LONGTON GM, ANASETTI C, et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 1997: 89: 1818-1823.
5. PETERSDORF EW, GOOLEY TA, ANASETTI C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998: 92: 3515-3520.
6. ANASETTI C, HANSEN JA. Bone marrow transplantation from HLA-partially matched related donors and unrelated volunteer donors. In: FORMAN SJ, BLUME KG, THOMAS ED, eds. Bone Marrow Transplantation. Boston: Blackwell Scientific Publictions 1994: 665-680.
7. MARTIS PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans. J Exp Med 1993: 178: 703-712.
8. MARTIN PJ. Prevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanism. Blood 1996: 88: 962-969.
9. KERNAN NA, FLOMENBERG N, DUPONT B, O'REILLY RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Transplantation 1987: 43: 842-847.
10. BUNJES D, HEIT W, ARNOLD R, et al. Evidence for the involvement of host-derived OKT8-positive T cells in the rejection of T-depleted, HLA-identical bone marrow grafts. Transplantation 1987: 43: 501-505.
11. LAMB LS JR, GEE AP, PARRISH RS, et al. Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: clinical and immunologic characteristics. Bone Marrow Transplant 1996: 17: 1021-1027.
12. TERENZI A, AVERSA F, ALBI N, et al. Residual clonable host cell detection for predicting engraftment of T cell depleted BMTs. Bone Marrow Transplant 1993: 11: 357-361.
13. OHLEN C, HOGLUND P, SENTMAN CL, et al. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules. Eur J Immunol 1995: 25: 1286-1291.
14. GEORGE T, YU YY, LIU J, et al. Allorecognition by murine natural killer cells: lysis of T-lymphoblasts and rejection of bone-marrow grafts (Review). Immunol Rev 1997: 155: 29-40.
15. BARGE AJ, JOHNSON G, WITHERSPOON R, TOROK-STORB B. Antibody-mediated marrow failure after allogenic bone marrow transplantation. Blood 1989: 74: 1477-1480.
16. STORE R, PRENTICE RL, THOMAS ED, et al. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anaemia. Br J Haematol 1983: 55: 573-585.
17. PAPADAKIS V, MACKINNON S, KERNAN NA. Differential effect of pre-transplant cytoreduction on recovery of day zero host circulating cells. Bone Marrow Transplant 1994: 14: 623-630.
18. STORB R, WEIDEN PL, SULLIVAN KM, et al. Second marrow transplants in patients with aplastic anemia rejecting the first graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 1987: 70: 116-121.
19. SLATTERY JT, SANDERS JE, BUCKNER CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995: 16: 31-42.
20. AVERSA F, TERENZI A, CARROTTI A, et al. Addition of thiotepa improves results in T-cell depleted bone marrow tranplantation for advanced leukemia (Abstract). Blood 1993: 83: 313a
21. WAGNER JL, DEEG HJ, SEIDEL K, et al. Bone marrow transplantation for severe aplastic anemia from genotypically HLA-nonidentical relatives: an update of the Seattle experience. Transplantation 1996: 61: 54-61.
22. MARMONT AM, HOROWITZ MM, GALE RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120-2130.
23. REISNER Y, MARTELLI MF. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells (Review). Immunol Today 1995: 16: 437-440.
24. HENSLEE-DOWNEY PJ, PARRISH RS, MACDONALD JS, et al. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant. Transplantation 1996: 61: 738-745.
25. PAPADOPOULOS EB, CARABASI MH, CASTRO-MALASPINA H, et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease. Blood 1998: 91: 1083-1090.
26. SLAVIN S, NAGLER A, NAPARSTEK E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998: 91: 756-763.
27. STORB R, YU C, WAGNER JL, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997: 89: 3048-3054.
28. BJERKE JW, LORENZ J, MARTIN PJ, STORB R, HANSEN JA, ANASETTI C Treatment of graft failure with anti-CD3 antibody BC3, glucocorticoids and infusion of donor hematopoietic cells (Abstract). Blood 1995: 86: 107a, no. 415.
29. CAVAZZANA-CALVO M, BORDIGONI P, MICHEL G, et al. A phase II trial of partially incompatible bone marrow transplantation for high-risk acute lymphoblastic leukaemia in children: prevention of graft rejection with anti-LFA-1 and anti-CD2 antibodies. Societe Francaise de Greffe de Moelle Osseuse. Br J Haematol 1996: 93: 131-138.
30. LAPIDOT T, TERENZI A, SINGER TS, SALOMON O, REISNER Y. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts. Blood 1989: 73: 2025-2032.
31. GENGOZIAN N, CARLSON DE, ALLEN EM. Transplantation of allogeneic and xenogeneic (rat) marrow in irradiated mice as affected by radiation exposure rates. Transplantation 1969: 7: 259-273.
32. LAPIDOT T, LUBIN I, TERENZI A, FAKTOROWICH Y, ERLICH P, REISNER Y. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity. Proc Natl Acad Sci USA 1990: 87: 4595-4599.
33. LEBKOWSKI JS, MCNALLY MA, FINCH S, et al. Enrichment of murine hematopoietic stem cells. Reconstitution of syngeneic and haplotype-mismatched mice. Transplantation 1990: 50: 1019-1027.
34. BACHAR-LUSTIG E, RACHAMIM N, LI HW, LAN F, REISNER Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995: 1: 1268-1273.
35. AVERSA F, TABILIO A, TERENZI A, et al. Successful engraftment of T-cell-depleted halpoidentical 'Three-Loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994: 11: 3948-3955.
36. OFFNER F, SCHOCH G, FISHER LD, TOROK-STORB B, MARTIN PJ. Mortality hazard functions as related to neutropenia at different times after marrow transplantation. Blood 1996: 88: 4058-4062.
37. KERNAN NA, BORDIGNON C, HELLER G, et al. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989: 74: 2227-2236.
38. ANASETTI C, TAN P, HANSEN JA, MARTIN PJ. Induction of specific nonresponsiveness in unprimed human T cell by anti-CD3 antibody and alloantigen. J Exp Med 1990: 172: 1691-1700.
39. ANASETTI C, MARTIN PJ, STORB R, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992: 54: 844-851.